Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
56 participants
INTERVENTIONAL
2008-04-30
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients
NCT01336062
Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients
NCT01641783
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
NCT05913115
Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer
NCT00983801
Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201
NCT07333820
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ABI-007
ABI-007
ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABI-007
ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received one prior regimen containing fluoropyrimidine analogs and developed disease progression or recurrence
* Age: 20 - 74
* At least one measurable lesion by RECIST criteria
Exclusion Criteria
* Patients with another active malignancy
* Pre-existing peripheral neuropathy of Grade 2, 3, or 4 (per CTCAE)
* Chronic treatment with steroids
20 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taiho Pharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nagahiro Saijo, MD
Role: STUDY_CHAIR
Kinki University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi Cancer Center
Nagoya, Aichi-ken, Japan
Shikoku Cancer Center
Matsuyama, Ehime, Japan
National Kyusyu Cancer Center
Fukuoka, Fukuoka, Japan
Kitasato University East Hospital
Sagamihara, Kanagawa, Japan
Kochi Health Sciences Center
Kochi, Kochi, Japan
Saku Central Hospital Nagano Prefectural Federation of Agricultural Cooperatives for Health and Welfare
Saku, Nagano, Japan
Osaka Medical College Hospital
Takatsuki, Osaka, Japan
Saitama International medical center-comprehensive cancer center, Saitama Medical University
Hidaka, Saitama, Japan
Shizuoka Cancer Center
Sunto, Shizuoka, Japan
Kouseiren Takaoka Hospital
Takaoka, Toyama, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, Koizumi W, Toh Y, Hara T, Miyata Y. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014 Jul;105(7):812-7. doi: 10.1111/cas.12419. Epub 2014 Jul 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Taiho10041040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.